INTRODUCTION
deaths, coronavirus disease 2019
CORONAVIRUS DISEASE 2019
Since its emergence in December 2019, coronavirus disease 2019 (COVID-19) has spread worldwide. As of 9 February 2022, the cumulative number of COVID-19 cases was over 399 million, including more than 5.8 million deaths (Camostat mesylate (DWJ1248, Foistar) is an orally bioavailable synthetic serine protease inhibitor and a strong inhibitor of trypsin, plasmin, plasma kallikrein, and thrombin (According to the literature, an Camostat mesylate is a promising candidate for the treatment of COVID-19, as it is orally bioavailable, affordable, and widely available. To explore the possibility of clinical benefit of camostat mesylate in the treatment of COVID-19, we conducted a randomized, placebo-controlled, phase 2 clinical trial in adult patients with mild to moderate COVID-19 (ClinicalTrials.gov registration no. NCT04521296).